Association between α1-antichymotrypsin signal peptide −15A/T polymorphism and the risk of Alzheimer’s disease: a meta-analysis
- 260 Downloads
No consensus has been recently reached at the relationship between the α1-antichymotrypsin (ACT) signal peptide −15A/T polymorphism and Alzheimer’s disease (AD) risk. Thus, our study aimed to better assess this association by performing a meta-analysis, including 4,212 cases and 4,039 controls from 29 studies. Odds ratios (ORs) with the 95% confidence interval (CI) were used to assess the strength of relationship between ACT −15A/T polymorphism and AD risk. Overall, a borderline statistically significant association was detected under recessive model comparison in all subjects (AA vs. AT+TT: OR 1.12, 95% CI 1.01–1.25, P = 0.04). But in subgroup analysis by ethnicity, no significant association was found in Caucasians, Asians, or Africans. Moreover, after exclusion of one study which affect the heterogeneity, the ACT A allele and AA genotype were statistically associated with late-onset AD (LOAD) risk (AA vs. TT: OR 1.25, 95% CI 1.06–1.48, P = 0.007, A vs. T: OR 1.12, 95% CI 1.03–1.21, P = 0.008), especially in Caucasians. In conclusion, our study suggests that the common α1-antichymotrypsin signal peptide −15A/T polymorphism may not be a major risk factor for AD. However, the polymorphism is capable of increasing LOAD risk.
Keywordsα1-Antichymotrypsin Alzheimer’s disease Meta-analysis Polymorphism
This study was supported by National Natural Science Foundation of China (No. 30470583).
Conflict of Interest
- 1.Katzman RN (1996) Medical progress: Alzheimer’s disease. N Engl J Med 274:964–973Google Scholar
- 16.Thome J, Baumer A, Kornhuber J, Rosler R, Riederer P (1995) Alpha-1-antichymotrypsin bi-allele polymorphism, apolipoprotein-E tri-allele polymorphism and genetic risk for Alzheimer’s syndrome. J Neural Transm 102:207–212Google Scholar
- 29.Didierjean O, Martinez M, Campion D, Hannequin D, Dubois B, Martin C, Puel M, Thomas Anterion C, Pasquier F, Moreau O, Babron MC, Penet C, Agid Y, Clerget-Darpoux F, Frebourg T, Brice A (1997) No effect of the α1-antichymotrypsin A allele in Alzheimer’s disease. J Neurol Neurosurg Psychiatry 63:103–105PubMedCrossRefGoogle Scholar
- 31.Martin TR, Calella AM, Silva S, Munna E, Modena P, Chiesa R, Terrevazzi S, Ruggieri RM, Palermo R, Piccoli F, Confalonieri R, Tiraboschi P, Fragiacomo C, Quadri P, Lucca U, Forloni G (2000) Apolipoprotein E and intronic polymorphism of presenilin 1 and alpha-1-antichymotrypsin in Alzheimer’s disease and vascular dementia. Dement Geriatr Cogn 11:239–244CrossRefGoogle Scholar
- 32.Haines JL, Pritchard ML, Saunders AM, Schildkraut JM, Growdon JH, Gaskell PC, Farrer LA, Auerbach SA, Gusella JF, Locke PA, Rosi BL, Yamaoka L, Small GW, Conneally PM, Roses AD, Pericak-vance MA (1996) No genetic effect of α1-antichymotrypsin in Alzheimer disease. Genomics 33:53–56PubMedCrossRefGoogle Scholar
- 38.Yoshiiwa A, Kamino K, Yamamoto H, Kobayashi T, Imagawa M, Nonomura Y, Yoneda H, Sakai T, Nishiwaki Y, Sato N, Rakugi H, Miki T, Ogihara T (1997) α1-Antichymotrypsin as a risk modifier for late-onset Alzheimer’s disease in Japanese apolipoprotein E ε 4 allele carriers. Ann Neurol 42:115–117PubMedCrossRefGoogle Scholar